Overview

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open label and single arm study to investigate the safety and efficacy of BEZ235 in adult women with endometrial carcinoma whose disease progressed (or recurred) while on or after first-line antineoplastic treatment for advanced endometrial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Dactolisib